TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07793942: A Phase 2, Open-label Clinical Study to Evaluate the Safety and Efficacy of MK-2010 as Monotherapy and in Combination

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 480 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07793942 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07793942 Rescue Dossier →